Abstract:Opinion statement Relapse is still a common scenario in acute myeloid leukemia (AML) treatment and occurs in 40–50% of younger and the great majority of elderly patients. The prognosis in relapsed AML patients is generally poor but depends largely on the timing of relapse (early versus late) and the possibility of allogeneic hematopoietic stem cell transplantation (HSCT). At the time of relapse, we again perform a mutational screening and cytogenetic analysis in all AML patients as clonal evolution of disease is frequent. Clinical trials should be first priority in all relapsed patients. In fit patients without prior transplant, we aim to perform HSCT after salvage therapy. In AML patients relapsing after HSCT and good performance status, intensive therapy can be considered with subsequent cellular therapy such as donor lymphocyte infusion (DLI) or a second HSCT. However, less than 20% of these patients are alive after 5 years. For those patients that are unfit, the therapeutic aim is to prolong life with acceptable quality of life. Here, hypomethylating agents (HMA), low-dose AraC (LDAC), and solely cytoreductive therapy with hydroxurea are options depending on first-line therapy. For those patients that have not been treated with venetoclax in first line, the combination therapy of venetoclax with demethylating agents achieves encouraging response rates. Venetoclax is currently also studied in combination with intensive salvage therapy. Importantly, for patients with isocitrate dehydrogenase ( IDH ) 1/ 2 –mutated AML, ivosidenib, an IDH1 inhibitor, and enasidenib, an IDH2 inhibitor, present well-tolerated options in the setting of refractory or relapsed (r/r) disease even in elderly and heavily pre-treated patients with response rates of 30–40%. Both substances have been approved by the U.S. Food and Drug Administration (FDA) for r/r AML patients with IDH1/2 mutations (but not yet by the European Medicines Agency (EMA)). For patients with FMS-like tyrosine kinase 3 ( FLT3) mutations, treatment with the selective FLT3 inhibitor gilteritinib is well tolerated and leads to improved outcome compared with standard salvage therapy. The approval has been granted by the FDA and the EMA. Generally, we would recommend targeted therapy for IDH1/2- and FLT3 -mutated AML if available. In order to improve outcome in relapsed AML, it will be important to intelligently combine novel substances with each other as well as chemotherapy in prospective clinical trials. The development of therapies with bispecific antibodies or chimeric antigen receptor T cells (CAR-T) are still in early development.

Treatment Options for Older Unfit Patients with Acute Myeloid Leukemia

Treatment of Acute Myeloid Leukemia in Older Adults

Non-intensive acute myeloid leukemia therapies for older patients

New Treatment Options for Older Patients with Acute Myeloid Leukemia

Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions

Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia

Recent advances in targeted therapies in acute myeloid leukemia

[Management of AML in the elderly]

Individual Treatment of Acute Myelogenous Leukemia in Elderly Patients

Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia

From New Biological Insights to Targeted Therapies

Treatment of Relapsed Acute Myeloid Leukemia

Research Progress in the Pharmacogenomics of Agents for Treatment of Acute Myeloid Leukemia

Advances in targeted therapy for acute myeloid leukemia

Acute myeloid leukemia: introduction to a series highlighting progress and ongoing challenges

Mitochondrial metabolism as a target for acute myeloid leukemia treatment

Transplant Eligible and Ineligible Elderly Patients with AML—A Genomic Approach and Next Generation Questions

A review of treatment options employed in relapsed/refractory AML

Contemporary Management of Acute Myeloid Leukemia: A Review

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older

How I treat refractory and relapsed acute myeloid leukemia